Eltrombopag Olamine Tablet, Film Coated
NDC Package 87564-032-30

11-digit billing NDC: 87564003230

Package Information

Eltrombopag Olamine tablets is eltrombopag tablets are thrombopoietin receptor agonist indicated:for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. This formulation utilizes a tablet, film coated delivery system. Marketed by Amerisyn, Llc, this product is identified by NDC 87564-032 and is authorized under FDA application ANDA219638.

Identification & Billing

NDC Package Code
87564-032-30
Package Description
30 TABLET, FILM COATED in 1 BOTTLE
Product Code
11-Digit Billing Format
87564003230
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Eltrombopag Olamine
Non-Proprietary Name
Eltrombopag Olamine
Substance Name
Eltrombopag Olamine
Dosage Form
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Eltrombopag tablets are thrombopoietin receptor agonist indicated:for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Eltrombopag tablets should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. (1.1)for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. Eltrombopag tablets should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy. (1.2)in combination with standard immunosuppressive therapy for the first- line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia. (1.3)for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. (1.3)Limitations of Use:Eltrombopag tablets are not indicated for the treatment of patients with myelodysplastic syndrome (MDS). (1.4)Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C infection. (1.4)

Regulatory & Marketing

Labeler Name
Amerisyn, Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA219638
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
06-30-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 87564-032-30 identifies a specific commercial package of 30 tablet, film coated in 1 bottle of Eltrombopag Olamine, a human prescription drug labeled by Amerisyn, Llc. This tablet, film coated is formulated for oral use and contains eltrombopag olamine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Amerisyn, Llc on June 30, 2026. The current certification is valid through December 31, 2027.

How is this Amerisyn, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 87564003230. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
87564-032-30
11-Digit CMS (5-4-2)
87564-0032-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.